Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver.

Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Review. No abstract available.


Ribavirin: Past, present and future.

Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P.

World J Hepatol. 2016 Jan 18;8(2):123-30. doi: 10.4254/wjh.v8.i2.123. Review.


Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation.

Hung AK, Guy J, Behler CM, Lee EE.

Case Rep Transplant. 2015;2015:286276. doi: 10.1155/2015/286276. Epub 2015 Jul 9.


Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease.

Ferrari M, Manea L, Anton K, Bruzzone P, Meneghello M, Zamboni F, Purgato L, Cazzoletti L, Ferrari P, Testi R.

BMC Pulm Med. 2015 May 8;15:58. doi: 10.1186/s12890-015-0050-y.


Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients.

Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M.

Glob J Health Sci. 2014 Nov 17;7(3):75-81. doi: 10.5539/gjhs.v7n3p75.


KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver (KASL).

Clin Mol Hepatol. 2014 Jun;20(2):89-136. doi: 10.3350/cmh.2014.20.2.89. Epub 2014 Jun 30. No abstract available.


Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis.

Cindoruk M, Karakan T, Unal S.

Curr Ther Res Clin Exp. 2005 Sep;66(5):451-62. doi: 10.1016/j.curtheres.2005.10.002.


Comparative study to evaluate the anti-viral efficacy of Glycyrrhiza glabra extract and ribavirin against the Newcastle disease virus.

Omer MO, Almalki WH, Shahid I, Khuram S, Altaf I, Imran S.

Pharmacognosy Res. 2014 Jan;6(1):6-11. doi: 10.4103/0974-8490.122911.


Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.

Barcaui HS, Tavares GC, May SB, Brandão-Mello CE, Amendola Pires MM, Barroso PF.

PLoS One. 2013 Jul 9;8(7):e67734. doi: 10.1371/journal.pone.0067734. Print 2013.


Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N.

World J Hepatol. 2013 May 27;5(5):237-50. doi: 10.4254/wjh.v5.i5.237.


What the infectious disease physician needs to know about pegylated interferon and ribavirin.

Gara N, Ghany MG.

Clin Infect Dis. 2013 Jun;56(11):1629-36. doi: 10.1093/cid/cit074. Epub 2013 Feb 21. Review.


The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Hassanein T, Shiffman ML, Zein NN.

Gastroenterol Hepatol (N Y). 2007 Jun;3(6 Suppl 20):4-32. No abstract available.


Hepatitis C virus: a critical appraisal of new approaches to therapy.

Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D.

Hepat Res Treat. 2012;2012:138302. doi: 10.1155/2012/138302. Epub 2012 Oct 8.


An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ.

Can J Gastroenterol. 2012 Jun;26(6):359-75.


Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group.

Aliment Pharmacol Ther. 2012 Aug;36(4):370-8. doi: 10.1111/j.1365-2036.2012.05188.x. Epub 2012 Jun 19.


Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.

Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J, Muñoz J, Vidal F, Baiget M.

Antimicrob Agents Chemother. 2012 Jun;56(6):2987-93. doi: 10.1128/AAC.06473-11. Epub 2012 Mar 19.


Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):261-8. doi: 10.1097/QAI.0b013e3182324af9.


The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.

Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE; ACTG A5178 Study Team.

Aliment Pharmacol Ther. 2011 Jun;33(11):1234-44. doi: 10.1111/j.1365-2036.2011.04648.x. Epub 2011 Mar 29.


Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.

Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J.

Mediterr J Hematol Infect Dis. 2010 Mar 31;2(1):e2010003. doi: 10.4084/MJHID.2010.003.

Supplemental Content

Support Center